Reaction
Radiation Necrosis reporting signals
As of the last recalculation, Radiation Necrosis appears in 562 FAERS reports alongside 23 co-occurring drug terms. The strongest observed disproportionality signal is ADO-TRASTUZUMAB EMTANSINE (PRR 199.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ado-Trastuzumab Emtansine | 42 | 199.3 | 200.3 |
| Temozolomide | 67 | 133.6 | 134.0 |
| Fam-Trastuzumab Deruxtecan-Nxki | 24 | 92.1 | 92.3 |
| Bevacizumab | 155 | 63.6 | 63.7 |
| Dexamethasone Sodium Phosphate | 12 | 44.7 | 44.7 |
| Vemurafenib | 12 | 37.8 | 37.8 |
| Trastuzumab | 60 | 36.1 | 36.2 |
| Ipilimumab | 38 | 34.9 | 34.9 |
| Lapatinib | 14 | 34.2 | 34.3 |
| Pertuzumab | 24 | 34.1 | 34.1 |
| Pemetrexed | 19 | 33.9 | 34.0 |
| Atezolizumab | 25 | 24.9 | 24.9 |
| Erlotinib | 6 | 23.2 | 23.2 |
| Gefitinib | 5 | 20.7 | 20.7 |
| Crizotinib | 7 | 20.6 | 20.6 |
| Pemetrexed Disodium | 20 | 20.1 | 20.1 |
| Pembrolizumab | 47 | 18.0 | 18.0 |
| Erlotinib Hydrochloride | 6 | 17.9 | 17.9 |
| Nivolumab | 43 | 17.8 | 17.8 |
| Encorafenib | 4 | 15.1 | 15.1 |
| Abemaciclib | 6 | 11.2 | 11.2 |
| Osimertinib | 9 | 10.6 | 10.6 |
| Durvalumab | 5 | 9.2 | 9.2 |